Palatin Technologies
Cranbury
About Palatin Technologies
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine’two of their targeted areas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $161.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: otcqb:PTNT
- Website: palatin.com
- Phone: 609-495-2200
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/palatin-technologies-7477 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.